Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Rectal Neoplasms 4Pancreatic Neoplasms 4Neoplasms 4Colonic Neoplasms 4Neoplasm Metastasis 3Colorectal Neoplasms 3Stomach Neoplasms 2Ovarian Neoplasms 2Melanoma 2Locally Advanced Rectal Cancer (LARC) 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Rhabdomyosarcoma 1Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) 1Osteosarcoma 1Neoplasms by Site 1MMR-D/MSI-H Colorectal Cancers 1Lung Neoplasms 1Hodgkin Disease 1Hepatoblastoma 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Ependymoma 1Endometrial Neoplasms 1

Interventions

Oxaliplatin 271Fluorouracil 268Capecitabine 235Leucovorin 209Irinotecan 152Radiotherapy 139Bevacizumab 114Cetuximab 82Surgical Procedures, Operative 51Folfox protocol 49Neoadjuvant Therapy 45Drug Therapy 43Radiation 42Chemotherapy, Adjuvant 34Chemoradiotherapy 34Panitumumab 27Magnetic Resonance Spectroscopy 26XELOX 25Radiotherapy, Intensity-Modulated 23Biopsy 20Surveys and Questionnaires 18Laparoscopy 18Proctectomy 17Floxuridine 17Early Intervention, Educational 16Nivolumab 15Immunohistochemistry 15Gene Expression Profiling 15Gemcitabine 15pembrolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Rectal Neoplasms × dostarlimab × Gastrointestinal × Clear all
NCT05723562 2026-05-26

AZUR-1

GlaxoSmithKline

Phase 2 Active not recruiting
154 enrolled
Gastrointestinal

Rectal Neoplasms

NCT04165772 2026-05-13

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
212 enrolled
Gastrointestinal

Rectal Neoplasms

NCT06640049 2025-11-17

China AZUR-1

GlaxoSmithKline

Phase 2 Active not recruiting
23 enrolled
Gastrointestinal

Rectal Neoplasms

NCT04926324 2025-06-29

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

University of Iowa

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡